Mirabegron was not tied to higher obesity-related neoplasm risk vs antimuscarinics in overactive bladder, but all-cause mortality was higher.
|Articles|September 2, 2014
Cabozantinib Fails in Phase 3
The company developing the drug, Excelis, now plans to focus it's attention on the ongoing kidney and liver cancer trials for the drug.
Advertisement
The so-called COMET-1 study enrolled 960 men with advanced prostate cancer no longer responding to treatment with the chemotherapy drug docetaxel, Johnson & Johnson's Zytiga and/or Medivation's Xtandi. The patients were randomized to treatment with cabozantinib or the steroid prednisone and followed for survival. As reported Monday, cabozantinib reduced the risk of death by 10% compared to prednisone but the difference was not statistically significant. The study failed to achieve its primary endpoint.
Complete report:
Source: The Street
Advertisement
Related to this article
NCCN now lists the brain-penetrant ROS1 inhibitor after progression on earlier TKIs, including as a preferred option for symptomatic brain progression.
Elagolix 150 mg was noninferior to dienogest 2 mg for reducing moderate-to-severe endometriosis pain in a phase 3 trial of 230 women in India.
Initial frontal fibrosing alopecia treatment was largely similar in Black and White patients, though tetracycline use was higher in Black patients.
Nearly half of patients with chronic HBV or HCV also had MASLD, tied to worse fatigue and quality of life.
Reductions in antibody function, not IgG titers, distinguishes efgartigimod responders in myasthenia gravis.
HHS does not intend to take enforcement action against pharmacies compounding BPC-157 and 5 other unapproved peptides if they meet 10 conditions.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Advertisement
Advertisement
Trending on AJMC
1
HHS Draft Policy Eases Enforcement on 6 Compounded Peptides
2
BPC-157 'Wolverine Peptide' Use Rose 33-Fold Despite Scant Evidence
3
5 Things to Know About HHS's Interim Peptide Compounding Policy
4
Elagolix Noninferior to Dienogest for Endometriosis Pain in Phase 3 Trial
5